Systemic MC activation occurs in the setting of bile duct obstruction, and targeting therapy against activation of MCs via CROM demonstrated multiple beneficial effects, such as regression of hepatobiliary injury and control of pruritus, possibly by decreasing various mediators, including ATX and histamine. This evidence concerns the gene ENPP2 and cholestasis.